Stock Blog Hub » ACOR

(ACOR) Company News for October 6, 2011 – Corporate Summary

vitalstocks — Thu, 06 Oct 2011 17:43:05 +0000

• Monsanto Co. (NYSE:MON) reported its fiscal fourth-quarter loss of $0.22 cents a share, better than the Zacks Consensus Estimate of a loss of $0.27. Revenues rose 15.1% year-over-year to $2.25 billion from $1.95 billion • Reacting to news that Microsoft (NASDAQ:MSFT) is considering a bid for Yahoo (NASDAQ:YHOO), shares of the company gained 3.30% [...]

(ACOR) Company News for October 6, 2011 – Corporate Summary

(ACOR) Acorda Therapeutics Gains – Earnings Miss Estimates

vitalstocks — Thu, 04 Aug 2011 15:47:42 +0000

Acorda Therapeutics Inc. (ACOR) recorded adjusted earnings of 7 cents per share for the second quarter of fiscal 2011, compared with a loss of 18 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 12 cents per share. Higher revenues during the quarter led to the surge in the company’s [...]

(ACOR) Acorda Therapeutics Gains – Earnings Miss Estimates

(ACOR) Company News for August 2, 2011 – Corporate Summary

vitalstocks — Tue, 02 Aug 2011 21:23:12 +0000

• Allstate Corporation (NYSE:ALL) reported Q2 loss of $1.23, lower than the Zacks Consensus Estimate of $1.53 per share. Revenues for the quarter increased by 5% year-over-year to $8.08 billion, exceeding the Zacks Consensus Estimate of $6.91 billion• Auxilium Pharmaceuticals (NASDAQ:AUXL) posted a Q2 loss of $0.11 per share, less than the analysts’ estimate for [...]

(ACOR) Company News for August 2, 2011 – Corporate Summary

(ACOR) Acorda Therapeutics Inks Deal with Medtronic

vitalstocks — Wed, 06 Jul 2011 21:18:33 +0000

Acorda Therapeutics, Inc. (ACOR) recently entered into a licensing agreement with Medtronic, Inc. (MDT) for AC105. The company acquired worldwide development and commercialization rights to AC105. The Candidate – AC105 Acorda intends to study AC105 as an acute treatment for patients who have suffered neurological trauma, such as spinal cord injury (SCI) and traumatic brain [...]

(ACOR) Acorda Therapeutics Inks Deal with Medtronic

(ACOR) Acorda Therapeutics Gets Mixed Data on Ampyra

vitalstocks — Thu, 16 Jun 2011 14:45:22 +0000

Acorda Therapeutics, Inc. (ACOR) recently reported an analysis of data on Ampyra (dalfampridine) at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. The analysis demonstrated improvements in walking ability of patients on Ampyra as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12). The analysis comprised data from a phase II [...]

(ACOR) Acorda Therapeutics Gets Mixed Data on Ampyra

(ACOR) Company News for May 23, 2011 – Corporate Summary

vitalstocks — Mon, 23 May 2011 17:58:38 +0000

• Shares of Morgan Stanley (NYSE:MS) were guided lower after FrontPoint Partners LLC decided to close some of its hedge funds in which Morgan Stanley holds a minor stake by this month • After a regulatory filing disclosed that the chief scientist of Akamai Technologies Inc. (NASDAQ:AKAM) had purchased 50,000 shares of its stock, the [...]

(ACOR) Company News for May 23, 2011 – Corporate Summary

(ALKS) Alkermesto Buy Elan Unit for $960 Million

vitalstocks — Mon, 09 May 2011 22:55:24 +0000

Recently, Alkermes, Inc. (ALKS) inked a deal with Elan Corporation (ELN) to buy the latter’s Elan Drug Technologies (EDT) segment. The EDT segment is the drug delivery unit of Elan. The merger, expected to close in the third quarter of calendar 2011, is worth approximately $960 million. The merged entity will be known as Alkermes [...]

(ALKS) Alkermesto Buy Elan Unit for $960 Million

(ACOR) Acorda Therapeutics Reports Loss That Missed Expectations

vitalstocks — Sun, 08 May 2011 15:50:53 +0000

Acorda Therapeutics Inc. (ACOR) posted a loss of 2 cents per share for the first quarter of fiscal 2011, compared with a loss of 56 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 18 cents per share. Despite increased revenues, higher operating expenses resulted in a loss during the [...]

(ACOR) Acorda Therapeutics Reports Loss That Missed Expectations

(BIIB) Biogen Idec Analyst Reduces Share Rating to Neutral

vitalstocks — Mon, 04 Oct 2010 05:07:10 +0000

We recently downgraded Biogen Idec, Inc. (BIIB) to Neutral from our previous Outperform recommendation. Biogen is one of the world’s largest biotechnology companies. Its main areas of focus include neurology, oncology, hemophilia and immunology. Products such as Avonex (for multiple sclerosis), Rituxan (for non-Hodgkin’s lymphoma), and Tysabri (for multiple sclerosis) currently drive the top line. [...]

(BIIB) Biogen Idec Analyst Reduces Share Rating to Neutral

(ABT) Pharma and Biotech Industry Outlook – July 2010 – Analyst Interviews

vitalstocks — Mon, 26 Jul 2010 14:58:05 +0000

The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main [...]

(ABT) Pharma and Biotech Industry Outlook – July 2010 – Analyst Interviews

(ABT) Pharma and Biotech Industry Outlook – July 2010 – Industry Outlook

vitalstocks — Wed, 21 Jul 2010 03:08:56 +0000

(ABT) Pharma and Biotech Industry Outlook – July 2010 – Industry Outlook

(BIIB) Biogen Idec and Abbott Laboratories Begin Patient Enrollment in Study

vitalstocks — Wed, 26 May 2010 23:23:29 +0000

Biogen Idec (BIIB) and Abbott (ABT) recently announced that they have started enrolling patients for their phase III study with daclizumab. The study– DECIDE, will evaluate the efficacy and safety of daclizumab in patients suffering from relapsing-remitting multiple sclerosis (RRMS). The candidate will be compared with Biogen’s Avonex. With the enrolment of the first patient, [...]

(BIIB) Biogen Idec and Abbott Laboratories Begin Patient Enrollment in Study

(ABT) Pharma & Biotech Stock Review – April 2010 – Industry Outlook

vitalstocks — Thu, 29 Apr 2010 14:10:15 +0000

The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the [...]

(ABT) Pharma & Biotech Stock Review – April 2010 – Industry Outlook

(RX) Pharma & Biotech Stock Review – Industry Outlook

vitalstocks — Sat, 30 Jan 2010 00:08:31 +0000

The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is [...]

(RX) Pharma & Biotech Stock Review – Industry Outlook

(ACOR) Acorda Therapeutics’ Multiple Sclerosis Drug Gets FDA Clearance

vitalstocks — Tue, 26 Jan 2010 04:36:31 +0000

Recently, Acorda Therapeutics Inc. (ACOR) announced that the U.S. Food and Drug Administration (FDA) has cleared its oral drug Ampyra (dalfampridine) which aims to improve walking speed in patients suffering from multiple sclerosis (MS). The company expects to launch the drug in the United States in March 2010. Ampyra is the first drug to get [...]

(ACOR) Acorda Therapeutics’ Multiple Sclerosis Drug Gets FDA Clearance

(BIIB) Biogen’s Tysabri is a Blockbuster!

vitalstocks — Wed, 13 Jan 2010 17:40:17 +0000

Biogen Idec Inc. (BIIB) recently announced that its multiple sclerosis (MS) drug Tysabri achieved blockbuster status in 2009. Sales of the drug, which is approved for relapsing forms of MS in the US and for relapsing-remitting MS in the EU, achieved $1 billion in sales in 2009. Tysabri is marketed by Biogen in collaboration with [...]

(BIIB) Biogen’s Tysabri is a Blockbuster!

(FACT) Facet Biotech Rejects Biogen Idec Again

vitalstocks — Fri, 11 Dec 2009 22:27:02 +0000

Facet Biotech Corp. (FACT) once again rejected Biogen Idec Inc.’s (BIIB) intention to acquire all the outstanding shares of Facet common stock stating that the revised offer is inadequate and not in the best interests of Facet Biotech’s stockholders. Earlier this month, Biogen had come back with a revised offer of $17.50 per share (up [...]

(FACT) Facet Biotech Rejects Biogen Idec Again

(RX) Big Pharma and Biotech – Industry Outlook

Shawn — Mon, 09 Nov 2009 23:57:38 +0000

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason [...]

(RX) Big Pharma and Biotech – Industry Outlook

(ACOR) Acorda Therapeutics – Bull of the Day

vitalstocks — Mon, 09 Nov 2009 03:22:14 +0000

Acorda Therapeutics (ACOR) is one of the more interesting biotechnology companies under our coverage. The company’s key pipeline drug, Fampridine-SR, is currently under U.S. FDA review, with a decision expected in late January 2010. Outside the U.S., Acorda has partnered with Biogen Idec under very favorable terms. Fampridine-SR has blockbuster potential worldwide in our view. [...]

(ACOR) Acorda Therapeutics – Bull of the Day

(BIIB) Biogen Reports Higher Earnings

vitalstocks — Tue, 20 Oct 2009 22:38:14 +0000

Today morning, Biogen Idec (BIIB) reported third quarter earnings per share of $1.12, beating the Zacks Consensus Estimate of $1.02. The company reported earnings of 98 cents in the year-ago period. Revenues increased 3% to $1.12 billion, with Tysabri being the primary growth driver. Tysabri sales came in at $207 million, up 21% from the [...]

(BIIB) Biogen Reports Higher Earnings

(BIIB) Biogen Extends Hostile Bid For Facet Biotech Corporation

vitalstocks — Tue, 20 Oct 2009 20:06:39 +0000

Biogen Idec Inc. (BIIB) extended its tender offer for the acquisition of all of the outstanding shares of Facet Biotech Corporation (FACT) to December 16, 2009. The offer was previously set to expire on October 19, 2009. As of October 15, 2009, about 28,336 shares of Facet Biotech stock have been tendered. Earlier this month, [...]

(BIIB) Biogen Extends Hostile Bid For Facet Biotech Corporation

(FACT) Facet Investors Urged to Deny Biogen Idec Tender Offer

vitalstocks — Mon, 12 Oct 2009 17:02:19 +0000

In line with expectations, Facet Biotech Corporation’s (FACT) board of directors unanimously recommended that its stockholders should reject the unsolicited conditional tender offer from Biogen Idec Inc. (BIIB), which is seeking to acquire all the outstanding shares of Facet Biotech common stock for $14.50 per share in cash. The board has determined that the offer [...]

(FACT) Facet Investors Urged to Deny Biogen Idec Tender Offer

(BIIB) Biogen Launches Hostile Bid for Partner Facet Biotech

vitalstocks — Thu, 24 Sep 2009 19:57:36 +0000

After being refused twice, Biogen Idec (BIIB) launched a hostile bid to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, by taking its offer directly to Facet’s shareholders. Biogen also sent a letter to Facet’s Board stating that Facet’s cash balance is less than Biogen’s offer price. The deal is valued at [...]

(BIIB) Biogen Launches Hostile Bid for Partner Facet Biotech